Cytarabine (Ara-C)
Sponsors
M.D. Anderson Cancer Center, Novartis Pharmaceuticals, First Affiliated Hospital of Zhejiang University, Kura Oncology, Inc., Joanna Yi
Conditions
Acute Myeloid Leukaemia (AML)Acute Myeloid LeukemiaAcute Myeloid Leukemia (AML)Acute T Lymphpblastic Leukemia/LymphomaChronic Myelogenous LeukemiaGraft Versus Host DiseaseLangerhans Cell HistiocytosisLeukemia
Early Phase 1
Phase 1
Phase 2
Peripheral Stem Cell Transplantation Plus Filgrastim in Treating Patients With Acute or Chronic Myelogenous Leukemia
CompletedNCT00002833
Start: 1994-10-31End: 2002-04-30Updated: 2012-07-30
VHAG in Treating R/R T-ALL/LBL
RecruitingNCT06742463
Start: 2024-12-31End: 2028-06-30Target: 50Updated: 2024-12-19
Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker
Not yet recruitingNCT07060001
Start: 2026-04-01End: 2029-12-01Target: 112Updated: 2026-03-06
Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML
RecruitingNCT07078591
Start: 2025-06-20End: 2031-06-30Target: 50Updated: 2025-07-28
Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH
RecruitingNCT07187193
Start: 2025-04-12End: 2027-04-13Target: 50Updated: 2025-09-22
Phase 3
Combination Chemotherapy in Treating Patients With Lymphoma
CompletedNCT00002835
Start: 1995-10-30End: 2004-02-04Updated: 2018-11-15
Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia
CompletedNCT00333840
Start: 2000-06-30End: 2012-03-31Updated: 2013-10-14
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
RecruitingNCT07007312
Start: 2025-09-26End: 2031-11-01Target: 1300Updated: 2026-03-13